Mrd in oncohaematology. Minimal cancer. Immune therapy of mrd.
08.50 Welcome address. Prof George Janossy, Prof Klaus Pantel, Prof Jean-Francois Rossi,
Prof Lydia Campos, Prof Bruno Brando & Dr Catherine Alix-Panabiиres09.10 Who should be Involved in harmonizing MRD detection on solid tumours in PB and BM.Andy Rawstron,Leeds, United Kingdom
09.50 MRD IN ONCOHAEMATOLOGY
Chairman: Prof Lydia Campos09.50 Prof Lydia Campos, Saint-Etienne, France. State of the art in acute myeloid leukemia minimal residual disease assessment.
10.10 Prof Christian Thiede, Dresden, Germany. NGS for upfront characterization and assessment of treatment response in AML and MDS.10.30 Prof Gerrit Jan Schuurhuis, Amsterdam, The Netherlands. Minimal residual disease in AML and the role of leukemia stem cells herein.
10.50 Coffee break11.20 French myeloid database: relevant tool for anticipation the most frequent recurrent genetic abnormalitie and to improve the acute myeloid leukaemia diagnostic. Dr Carmen Aanei, Saint-Etienne, France
11.40 MINIMAL CANCER
Chairmen:Prof Klaus Pantel & Dr Catherine Alix-Panabiиres11.40 Circulating and disseminated tumor cells: biology and clinical significance.Prof Klaus Pantel, Hamburg, Germany
13.00 Selected poster presentations
13.00 Selection of DNA aptamers to human Interleukin-6 (hIL6). Vera A. Spiridonova, Moscow, Russia
13.05 Influence of c-MYC hyperexpression and RAS genes mutations on the disease prognosis and therapy response in multiple myeloma patients. M. V. Nareyko, E. Y. Demidova, A. M. Sergeeva,V. L. Surin & L. P. Mendeleeva, Moscow, Russia
13.10 Lunch14.20 New data on DTC detection and monitoring by flow cytometry. Olga Beznos, Moscow, Russia
14.50 Flow Cytometry for the identification of rare cells. Sara de Biasi, Modena, Italy
15.20 IMMUNE THERAPY OF MRD
Chairmen: Prof Jean-Francois Rossi, Katherina Psarra & Prof Bruno Brando15.20 Myeloid suppressor cells in hematological malignancies. Katherina Psarra, Athens, Greece
16.20 Coffee break16.50 Prof Jean-Francois Rossi, Montpellier, France. New frontiers in immunopathology: from dysimmune diseases to lymphoid malignancies.